多發性骨髓瘤治療市場規模、佔有率、成長分析、按治療類型、按給藥途徑、按疾病類型、按最終用途、按地區 - 行業預測，2025-2032

2023 年全球多發性骨髓瘤治療市場規模價值 248 億美元，預計將從 2024 年的 263.6 億美元成長到 2032 年的 429.8 億美元，預測期內（2025-2032 年）的複合年成長率為 6.3%。

由於這种血液癌症的性質複雜，會損害骨髓並抑制漿細胞的產生，全球多發性骨髓瘤治療市場正在經歷顯著成長。這種快速成長背後的主要因素是人口老化和對疾病分子機制的認知不斷提高。幹細胞移植、免疫調節藥物、蛋白酶體抑制劑和單株抗體等專門而強效治療方法的開發創新進展也推動了市場擴張。此外，製藥公司正在大力投資研究，以生產尖端治療方法和個人化醫療策略，進一步加劇了激烈的競爭。製藥公司、生技公司和研究機構之間的合作推動了有效且副作用較少的治療方法的推出，尤其是單株抗體和CAR-T細胞療法，標誌著治療選擇的重要里程碑。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

多發性骨髓瘤治療市場規模（依治療類型）

• 市場概況
• 化療
• 標靶治療
• 免疫調節劑
• 幹細胞移植
• 放射治療
• 其他類型的治療

多發性骨髓瘤治療市場規模（依給藥途徑）

• 市場概況
• 口服
• 腸外

多發性骨髓瘤治療市場規模（依疾病類型）

• 市場概況
• 活動性多發性骨髓瘤
• 冒煙型多發性骨髓瘤

多發性骨髓瘤治療市場規模（依最終用途）

• 市場概況
• 醫院
• 專科門診
• 居家照護環境
• 其他最終用戶

多發性骨髓瘤治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Bristol Myers Squibb（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Amgen Inc.（USA）
• Sanofi SA（France）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• GlaxoSmithKline plc（UK）
• Novartis AG（Switzerland）
• Pfizer Inc.（USA）
• Celgene Corporation（USA）
• Karyopharm Therapeutics Inc.（USA）
• Ono Pharmaceutical Co., Ltd.（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Genmab A/S（Denmark）
• Adaptive Biotechnologies Corporation（USA）
• Legend Biotech Corporation（China）
• MorphoSys AG（Germany）
• bluebird bio, Inc.（USA）
• Secura Bio, Inc.（USA）
• BeiGene, Ltd.（China）

結論和建議

Global Multiple Myeloma Therapeutics Market size was valued at USD 24.8 billion in 2023 and is poised to grow from USD 26.36 billion in 2024 to USD 42.98 billion by 2032, growing at a CAGR of 6.3% during the forecast period (2025-2032).

The global multiple myeloma therapeutics market has experienced significant growth due to the complex nature of this hematological cancer, which damages bone marrow and disrupts plasma cell production. This surge is largely attributed to an aging population and heightened awareness of the disease's molecular mechanisms. Innovative advancements in the development of specialized and potent therapies, including stem cell transplants, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, have also fueled market expansion. Furthermore, pharmaceutical companies are heavily investing in research to create cutting-edge treatments and personalized care strategies, fostering a highly competitive landscape. Collaborations between pharma firms, biotech companies, and research institutions are driving the introduction of effective, low-side-effect therapies, notably monoclonal antibodies and CAR-T cell therapies, marking significant milestones in treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Myeloma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Myeloma Therapeutics Market Segmental Analysis

Global Multiple Myeloma Therapeutics Market is segmented by Treatment Type, Route of Administration, Disease Type, End-use and region. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted therapy, Immunomodulating agents, Stem cell transplantation, Radiation therapy and Other treatment types. Based on Route of Administration, the market is segmented into Oral and Parenteral. Based on Disease Type, the market is segmented into Active multiple myeloma and Smoldering multiple myeloma. Based on End-use, the market is segmented into Hospitals, Specialty clinics, Homecare settings and Other end-users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiple Myeloma Therapeutics Market

One of the key drivers of the global Multiple Myeloma Therapeutics market is the significant advancements in treatment options. Recent discoveries in innovative therapies, including monoclonal antibodies, proteasome inhibitors, and immunomodulatory drugs (IMiDs), have proven to be highly beneficial. These cutting-edge medications are designed to specifically target cancer cells while minimizing harm to healthy cells, resulting in improved treatment efficacy. This progress has led to higher patient survival rates and enhanced quality of life following treatment. As researchers and pharmaceutical companies continue to develop these novel therapies, they further propel the growth and potential of the multiple myeloma therapeutics market.

Restraints in the Global Multiple Myeloma Therapeutics Market

The Global Multiple Myeloma Therapeutics market faces significant restraints, primarily due to the high costs associated with treatment options. Despite advancements that have enhanced patient outcomes through the introduction of various innovative therapies, the steep price tags attached to these treatments can create barriers for patients, particularly those in economically challenged regions or with limited access to healthcare services. This financial obstacle may discourage the adoption of state-of-the-art therapies, ultimately restricting the market's growth potential. Consequently, addressing affordability and accessibility is crucial to ensure that promising treatment options reach the patients who need them the most.

Market Trends of the Global Multiple Myeloma Therapeutics Market

The Global Multiple Myeloma Therapeutics market is witnessing a significant shift towards advancements in targeted therapies and immunotherapies, reflecting a broader trend of precision medicine in oncology. As traditional chemotherapy presents limitations in efficacy and adverse effects, pharmaceutical companies are increasingly investing in developing innovative treatments that specifically target malignant cells while preserving healthy tissues. This focus includes the creation of monoclonal antibodies and specialized agents designed to inhibit myeloma cell proliferation. Furthermore, cutting-edge immunotherapy approaches, such as CAR-T cell therapy, have demonstrated promising results in clinical trials, offering patients more personalized and effective treatment options, thus propelling market growth and investment in novel therapeutic modalities.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Multiple Myeloma Therapeutics Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Targeted therapy
• Immunomodulating agents
• Stem cell transplantation
• Radiation therapy
• Other treatment types

Global Multiple Myeloma Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral

Global Multiple Myeloma Therapeutics Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Active multiple myeloma
• Smoldering multiple myeloma

Global Multiple Myeloma Therapeutics Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty clinics
• Homecare settings
• Other end-users

Global Multiple Myeloma Therapeutics Market Size & CAGR (2025-2032)

• North America (Treatment Type, Route of Administration, Disease Type, End-use)
  • US
  • Canada
• Europe (Treatment Type, Route of Administration, Disease Type, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Route of Administration, Disease Type, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Route of Administration, Disease Type, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Route of Administration, Disease Type, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ono Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptive Biotechnologies Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Legend Biotech Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MorphoSys AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bluebird bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Secura Bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations